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http://dx.doi.org/10.1016/j.jaci.2016.09.024Methods: We randomly assigned 93 adults with grass pollen–
induced allergic rhinitis to receive 7 preseasonal intradermal
allergen injections (containing 7 ng of Phl p 5 major
allergen) or a histamine control. The primary end point was
daily combined symptom-medication scores during the 2013
pollen season (area under the curve). Analysis was by
intention to treat. Skin biopsy specimens were collected after
intradermal allergen challenges, and late-phase responses
were measured 4 and 7, 10, or 13 months after treatment.
Results: There was no significant difference in the primary end
point between treatment arms (active, n 5 46; control, n 5 47;
median difference, 14; 95% CI, 2172.5 to 215.1; P 5 .80).
Among secondary end points, nasal symptoms were worse in the
intradermal treatment group, as measured based on daily
(median difference, 35; 95% CI, 4.0-67.5; P 5 .03) and visual
analog scale (median difference, 53; 95% CI, 211.6 to 125.2;
P 5 .05) scores. In a per-protocol analysis intradermal
immunotherapy was further associated with worse asthma
symptoms and fewer symptom-free days. Intradermal
immunotherapy increased serum Phleum pratense–specific IgE
levels (P 5 .001) compared with those in the control arm. T cells
cultured from biopsy specimens of subjects undergoing
intradermal immunotherapy had higher expression of the TH2
surface marker CRTH2 (P 5 .04) and lower expression of the
TH1 marker CXCR3 (P 5 .01), respectively. Late-phase
responses remained inhibited 7 months after treatment (P5 .03).
Conclusion: Intradermal allergen immunotherapy suppressed
skin late-phase responses but was not clinically effective and
resulted in worsening of respiratory allergic symptoms. (J
Allergy Clin Immunol 2016;nnn:nnn-nnn.)
Key words: Allergy immunotherapy, allergic rhinitis, grass pollen,
Phleum pratense, immunotherapy, intradermal, low dose
Immunotherapy with grass pollen for seasonal allergic rhinitis
is a longstanding and clinically effective treatment.1,2 Conven-
tional immunotherapy vaccines involve administration of high
doses of allergen (typically 10- to 20-mg quantities of major aller-
gens) by means of regular subcutaneous injection or as daily sub-
lingual tablets, although both approaches have limitations.
Subcutaneous immunotherapy is associated with a risk of sys-
temic allergic reactions, and therefore injections require specialist
supervision. Sublingual immunotherapy requires daily self-
dosing for 3 years, and nonadherence is relatively commonplace.3
Intradermal allergen injection in sensitized subjects results in a
localized wheal with erythema within 15 minutes (early-phase
response), followed by diffuse indurated swelling that persists for1
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2 SLOVICK ET ALAbbreviations usedAPAAP: Alkaline phosphatase–anti-alkaline phosphataseARIA: Allergic Rhinitis and Its Impact on AsthmaAUC: Area under the curveBU: Biological unitsCRTH2: Chemoattractant receptor-homologous molecule
expressed on TH2 lymphocytesCXCR3: Chemokine (C-X-C motif) receptor 3DC: Dendritic cellIQR: Interquartile rangeMini-RQLQ: Mini-Rhinoconjunctivitis Quality of Life QuestionnairePE: PhycoerythrinPollenLITE: Pollen Low Dose Intradermal Therapy EvaluationVAS: Visual analog scaleWAO: World Allergy Organization24 to 36 hours (late-phase response). The late-phase response is
accompanied by infiltration of activated TH2 cells, eosinophils,
and basophils, features that characterize chronic allergic inflam-
matory responses.4We previously reported that repeated intrader-
mal injections of grass pollen extract every 2 weeks lead to
progressive and systemic attenuation of the macroscopic skin
late-phase responses induced by these injections.5 After 6 intra-
dermal injections, each containing the equivalent of 7 ng of the
major allergen Phl p 5, late-phase responses were more than
90% suppressed, which is comparable with the degree of suppres-
sion achieved after conventional subcutaneous grass pollen
immunotherapy containing more than 1000-fold greater cumula-
tive allergen doses.
The concept of intradermal grass pollen allergen inoculation as
a treatment for allergic rhinitis is not without precedent. In 1926,
Phillips,6 a physician in Arizona, published a preliminary account
of his experiences with intradermal grass pollen immunotherapy
in 29 patients, which was extended to 322 patients by 1933,7 re-
porting that more than 90% obtained ‘‘satisfactory relief.’’ Here
we report the findings of the first randomized placebo-
controlled clinical trial of intradermal grass pollen injections
for seasonal grass pollen allergy. The Pollen Low Dose Intrader-
mal Therapy Evaluation (PollenLITE) studywas conceived to test
the hypothesis that skin late-phase response suppression after in-
tradermal grass pollen administration is associated with clinical
improvement in adults with seasonal allergic rhinitis.
METHODS
Study design
PollenLITE was a single-center, randomized, placebo-controlled, double-
blind phase 2 trial conducted at Guy’s Hospital in London, investigating the
efficacy and safety of 7 preseasonal intradermal injections of Phleum pratense
(timothy grass) pollen extract versus a histamine control (Fig 1). The National
Research Ethics Service Committee London-Harrow (12/LO/0941) and Med-
icines & Healthcare Products Regulatory Agency approved the study, with
oversight by King’s Health Partners Clinical Trial Office and an independent
trial steering committee. The clinical trial protocol8 was finalized before
randomization, and the statistical analysis plan was finalized before unblind-
ing and data analysis. All participants provided written informed consent in
accordance with the Declaration of Helsinki.
Participant selection
Ninety-three participants were recruited by using advertisements in the
press, online, and on public transport and a dedicated trial Web site. Eligibleparticipants were aged 18 to 65 years with moderate-to-severe grass pollen–
induced allergic rhinitis according to Allergic Rhinitis and Its Impact on
Asthma (ARIA) classification,9 positive skin prick test responses (>_3 mm in
diameter), and specific IgE levels (>_class 2) to P pratense. Exclusion criteria
included seasonal grass pollen–induced asthma requiring regular albuterol or
inhaled corticosteroids; symptomatic seasonal allergic rhinitis, asthma, or
both caused by tree or weed pollen overlapping the grass season requiring reg-
ular treatment; and perennial rhinitis and previous life-threatening anaphy-
laxis. The full inclusion and exclusion criteria are described in the Methods
section in this article’s Online Repository at www.jacionline.org.Randomization
Participants were randomized 1:1 by the King’s Clinical Trial Unit using
block randomization with a 24-hour Web-based system, with stratification
according to skin test response size to grass pollen and the presence of rhinitis
symptoms outside the grass pollen season.Study procedures
Seven intradermal active or control histamine forearm injections were
administered every 2 weeks before the 2013 grass pollen season (February 18
to May 24, 2013). Each active injection contained 10 biological units (BU)
(33.3 SQ-U; 7 ng of the major allergen Phl p 5) of P pratense (Aquagen SQ
Timothy; ALK-Abello, Reading, United Kingdom) in a 20-mL volume. This
regimen was chosen based on our previous study showing that 6 injections
at the same dose and interval led to 90% suppression of the late-phase response
in the skin. Histamine control was administered at 100 mg/mL for the first 2
injections, reduced to 30 mg/mL for the second 2 injections, and then reduced
10 mg/mL for the final injections to help preserve blinding. Details of active
and placebo manufacture are supplied in the Methods section in this article’s
Online Repository. Antihistamines were avoided 5 days before intradermal in-
jections, so that a wheal in response to the injection could be confirmed. All
participants were observed for systemic reactions after the first injection for
1 hour and for 30 minutes after subsequent injections. Participants completed
diary cards during the 2013 grass pollen season, recording symptoms and
rescue medication use.Study outcomes
The primary outcome was a combined symptom and medication score
during the grass pollen season (May 13 to August 31, 2013; 111 days), as
recommended by World Allergy Organization (WAO) guidelines for allergic
rhinitis immunotherapy trials (see the Methods section in this article’s Online
Repository for details of symptom and medication scoring).10
Predefined secondary clinical end points were overall symptom scores;
individual nose, mouth, eye, and lung symptom scores; overall medication
scores; combined symptom and medication scores during the peak season;
visual analog scale (VAS) scores for nose and eye symptoms (every 2 weeks);
mini-Rhinoconjunctivitis Quality of Life Questionnaire (mini-RQLQ) and
health-related quality of life (EQ-5D-5L) scores (4 time points); a global
evaluation of symptoms (at the end of the season); number of symptom and
medication-free days; and number of days prednisone was used. Adverse
events were recorded for all patients who received at least 1 dose of study drug
(see the Methods section in this article’s Online Repository). To verify blind-
ing, participants guessed whether they had received the active or control inter-
vention after the 2013 pollen season.
In September 2013 (ie, 4 months after completion of intradermal treatment
injections), cutaneous early-phase (15 minutes) and late-phase (24 hours)
responsesweremeasured after intradermal injections of grass pollen (identical
to treatment dose) and diluent (ALK-Abello). Twenty participants per
treatment arm were also randomized to undergo 3-mm punch biopsies from
these sites after 24 hours. Biopsy specimens were all analyzed by means of
immunohistochemistry for numbers of eosinophils, neutrophils, CD31 T
cells, and CD41 T cells. In half of participants who underwent biopsy, the bi-
opsy specimens were divided into 2 fragments, with the second fragment used
for T-cell expansion, flow cytometric evaluation of TH1/TH2 markers, and
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FIG 1. Study design.
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FIG 2. CONSORT diagram. All randomized participants were included in the intention-to-treat (ITT) anal-
ysis. Only participants who adequately adhered to treatment and rescue medications were included in
the per-protocol analysis.
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SLOVICK ET AL 3microarray analysis. Blood specimens were collected for P pratense–specific
IgE and IgG levels and basophil activation studies. Subjects were also random-
ized for repeat late-phase response measurements at either 7, 10, or 13 months
after treatment completion. Further methodological information is provided in
the Methods section in this article’s Online Repository.Statistical analysis
Details of the power calculation are provided in the Methods section in this
article’s Online Repository. All analyses were predefined in a detailed statis-
tical analysis plan and overseen by a data monitoring committee. Primary
outcome analysis, performed on an intention-to-treat basis, included all
TABLE I. Baseline characteristics of study participants
Characteristic
Control
subjects
(n 5 47)
Subjects
receiving
intradermal
immunotherapy
(n 5 46)
Age (y), mean (SD) 35 (10.8) 32 (9.9)
Female sex, no. (%) 12 (26) 19 (41)
Race, no. (%)
White 37 (79) 37 (80)
Mixed 2 (4) 3 (7)
Asian 3 (6) 4 (9)
Black 3 (6) 0 (0)
Other 2 (4) 2 (4)
Allergy symptoms outside grass pollen
season, no. (%)
18 (38) 16 (35)
Total IgE (kU/L), median (IQR) 121 (64-255) 160 (80-263)
P pratense–specific IgE (kUA/L),
median (IQR)
27 (10-54) 22 (9-49)
P pratense–specific SPT wheal diameter 12 (4.2) 11 (5.0)
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ferences between the groups in the area under the curve (AUC) of combined
symptom andmedication scores, the primary outcome, were assessed by using
a stratified Mann-Whitney U test (van Elteren test) adjusted for baseline strat-
ification factors. The stratified Hodges-Lehmann estimation was used to
calculatemedian differenceswith CIs. Similar analyseswere conducted for to-
tal and organ symptom scores, medication scores, and VAS scores. Mini-
RQLQ and EQ-5D-5L scores were evaluated by using linear mixed models
with 95%CIs. Sensitivity analyses were performedwith missing data imputed
by using mean scores on the day concerned and in the relevant trial arm for
primary and secondary outcomes in the intention-to-treat population. Ana-
lyses were also performed in the predefined per-protocol population. All
mechanistic analyses were performed with the Mann-Whitney U test, except
serology and immunohistochemistry, which were analyzed by means of anal-
ysis of covariance. The Wilcoxon signed-rank test was used to compare pre-
treatment versus posttreatment serology and diluent control versus allergen
challenge immunohistochemistry results.
The principal software package was SAS/STAT (SAS Institute, Cary, NC),
with verification of results from Syntax for selected analyses analyzed in Stata
(StataCorp, College Station, Tex). This trial was registered with Current
Controlled Trials (no. ISRCTN 78413121).
(mm), mean (SD)
Positive SPT response, no. (%)
Timothy grass 47 (100) 46 (100)
Mixed grass 47 (100) 46 (100)
Silver birch 19 (40) 24 (52)
Mugwort 11 (23) 9 (20)
House dust mite 28 (60) 24 (52)
Cat 24 (51) 18 (39)
Dog 41 (87) 36 (78)
Horse 4 (9) 6 (13)
Aspergillus species 1 (2) 2 (4)
Alternaria species 6 (13) 7 (15)
Cladosporium species 2 (4) 2 (4)
Seasonal asthma controlled with albuterol 17 (36) 15 (33)
SPT, Skin prick test.RESULTS
Study participants
A total of 93 participants were randomized. All could be
evaluated for the primary outcome in the intention-to-treat
analysis (Fig 2). Baseline characteristics were well balanced
between groups (Table I). All 46 participants receiving intra-
dermal allergen immunotherapy completed the treatment
course; one delayed an injection by 1 day because of a sched-
uling conflict. One of 47 participants assigned to control injec-
tions withdrew after the second injection because of work
commitments, and another delayed an injection by 4 days
because of an upper respiratory tract infection. Missing diary
data for the primary end point were few, with 94% of partici-
pants supplying more than 90% of daily data. One patient
completed less than the predetermined per-protocol 50%
threshold of daily data and was excluded from the per-
protocol population. Five participants, all in the control arm,
significantly deviated from protocol-specified use of rescue
medications. After the pollen season, participants were unable
to identify whether they had received active allergen or hista-
mine control treatment (see Table E1 in this article’s Online
Repository at www.jacionline.org).Primary outcome
There was a clear temporal relationship between the combined
symptom and medication scores and daily pollen counts (Fig 3,
A), which peaked at above-average levels. Intradermal immuno-
therapy did not significantly affect the primary end point (ie,
the combined symptom andmedication score over the entire grass
pollen season [111 days]; difference in median AUC, 14; 95%CI,
2172.5 to 215.1; P 5 .80; Fig 3, B; Table II).Secondary outcomes
No significant group differences were seen in secondary end
points of overall symptom scores (P5 .24) and rescue medication
use (P 5 .44) during the whole season and combined symptom
and medication scores during the peak season (June 12 to July
26, 2013; P 5 .90; Table II).Among other secondary end points, allergic rhinitis symptoms
measured based on daily nasal symptom scores were 44% higher
in the intradermal allergen immunotherapy group, with a differ-
ence in median AUC of 35 (95% CI, 4.0-67.5; P5 .03; Fig 3, C).
Rhinitis symptoms measured by using a VAS were 28% higher in
the intradermal allergen immunotherapy group, with a difference
inmedian AUC of 53 (95%CI,211.6 to 125.2;P5 .05; Fig 3,D).
No significant differences were seen between groups in daily eye
or lung symptoms (Table II), althoughmouth symptoms tended to
be more frequent in the intradermal allergen group (median dif-
ference in AUC, 10.0; 95% CI, 3.8-24; P 5 .05). No significant
group differences were observed in eye symptoms measured by
using VAS scores, mini-RQLQ scores, EQ-5D-5L scores, global
evaluation of symptoms scores, number of symptom or
medication-free days, or number of days prednisone was taken.
In the per-protocol analysis (Table III) the individual nasal
(P5 .02) and mouth (P5 .02) daily symptom scores were signif-
icantly higher in the active group, whereas lung daily symptom
scores (P5 .05) and overall symptom scores (P5 .09) tended to-
ward significance. Active group participants also had significantly
worse nasal symptoms measured by using VASs (P 5 .008) and
recorded fewer symptom-free days than subjects in the control
group (P 5 .04). In the intention-to-treat analysis, when missing
data were imputed (see Table E2 in this article’s Online Reposi-
tory at www.jacionline.org), nasal daily symptom scores
(P 5 .03) and VAS nasal symptom scores were statistically
FIG 3. Primary outcome and nasal symptoms. A,Mean daily combined symptom and medication scores in
the primary intention-to-treat analysis. Broken vertical lines indicate the beginning and end of the peak pol-
len season (June 12 to July 26, 2013). B, Daily grass pollen counts in central London during the 2013 grass
pollen season. C,Mean daily nasal symptom scores (sum of scores for sneezing, blockage, and running). D,
Mean nasal symptoms measured by using a VAS (total of blockage, running, itching, and sneezing). AUC
values for each participant were compared according to treatment arm. P values are based on the Mann-
Whitney U test.
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(P 5 .05).
Because allergic rhinitis nasal symptoms were unexpectedly
worse in intradermal immunotherapy participants, we performed
post hoc analyses comparing daily data for each individual
allergic symptom between groups (Table IV). In the active group
scores for sneezing (P 5 .01), cough (P 5 .02), chest tightness
(P 5 .08), and mouth itching (P 5 .06) were higher, whereas
eye swelling scores were lower (P5 .03). Individual nasal symp-
toms measured by using VAS scores also revealed higher scores
after intradermal immunotherapy for rhinorrhea (P 5 .006),
sneezing (P 5 .006), and nasal itching (P 5 .003, Table IV).
The frequency of adverse events was similar between groups.
The frequency of treatment-related adverse events was low: 3
(6.5%) and 6 (13%) participants in the intradermal immuno-
therapy and control groups, respectively, experienced mild
systematic reactions manifested as generalized pruritus only,
except for 1 participant receiving intradermal allergen who had
erythema tracking from the injection site in a lymphatic distri-
bution (IgE-mediated lymphangitis) 20 minutes after each injec-
tion. There were 3 serious adverse events all unrelated totreatment: 1 (2.2%) in the active group and 2 (4.3%) in the
control group (see Table E3 in this article’s Online Repository at
www.jacionline.org).Immunologic findings
Serologic assessments before (October 2012) and after (May
2013) treatment showed a typical seasonal decrease in allergen-
specific IgE levels in the control group (P < .001), which was
significantly less in the intradermal allergen immunotherapy
group (P5 .001), indicating a treatment-induced relative increase
in allergen-specific IgE levels (Fig 4, A). A treatment effect was
also seen on P pratense–specific IgG (P 5 .03; Fig 4, B) and
IgE titers to the major grass allergens Phl p 5 and Phl p 1 (see
Fig E1 in this article’s Online Repository at www.jacionline.
org), although no effect was seen on IgG4 responses (data not
shown).
CD41 T cells expanded from 19 of 20 skin biopsy specimens
collected after intradermal grass pollen challenge after the 2013
grass pollen season showed higher expression of the TH2 marker
chemoattractant receptor-homologous molecule expressed on
TABLE II. Effect of intradermal immunotherapy on primary and secondary outcomes (intention-to-treat analysis)
Clinical outcome
Control subjects
(n 5 47), median (IQR)
Subjects receiving
intradermal immunotherapy
(n 5 46), median (IQR) Difference (95% CI) P value
Primary outcome
CSMS during entire season 487 (365-717) 502 (333-841) 14 (2172.5 to 215.1) .80
Secondary outcomes
Symptom score during entire season 264 (156-398) 335 (183-503) 59 (21.3 to 110.9) .24
Medication score during entire season 263 (129-482) 242 (116-405) 219 (2153.0 to 100.2) .44
CSMS during peak season 365 (278-508) 356 (232-521) 28 (275.8 to 66.3) .90
Nasal symptom score during entire season 121 (81-200) 174 (120-207) 35 (4.0 to 67.5) .03
Mouth symptom score during entire season 14 (5-45) 34 (8-90) 10 (3.8 to 24) .05
Eye symptom score during entire season 78 (52-180) 79 (41-153) 27 (218.5 to 2.9) .54
Lung symptom score during entire season 12 (0-34) 17 (3-32) 4 (21 to 15) .17
Nasal allergic symptoms measured by VAS 122 (54-184) 156 (104-275) 53 (211.6 to 125.2) .05
Eye allergic symptoms measured by VAS 144 (41-176) 84 (32-197) 23 (246.0 to 35.8) .40
Global evaluation of symptom scores 3 (1-4) 3 (2-4) 0 (0 to 1) .48
Symptom-free days 41 (23-61) 35 (19-53) 26 (217 to 3) .15
No. of days prednisone used during entire season 0 (0-0) 0 (0-0) 0 (0 to 0) .36
Medication-free days 76 (65-94) 81 (65-93) 4 (211 to 21) .22
Mini-RQLQ 18 (10-25) 16 (13-23) 20.3 (24.2 to 3.7) .89
EQ-5D-5L 88 (81-94) 87 (83-94) 9 (224.8 to 43.6) .59
Median difference between groups was calculated by using stratified Hodges-Lehmann estimation. P values were based on the stratified Mann-Whitney U (Van Elteren) test
adjusted for stratification factors. P values for mini-RQLQ and EQ-5D-5L scores were based on linear mixed model adjusted for stratification factor. The entire grass pollen season
was from May 13-August 31, 2013; the peak season was from June 12-July 26, 2013.
CSMS, Combined symptom and medication score; EQ-5D-5L, EuroQoL instrument.
TABLE III. Effect of intradermal immunotherapy on primary and secondary outcomes (per-protocol sensitivity analysis)
Clinical outcome
Control subjects
(n 5 39), median (IQR)
Subjects receiving
intradermal immunotherapy
(n 5 45), median (IQR) Difference (95% CI) P value
Primary outcome
CSMS during entire season 453 (279-685) 517 (344-841) 82 (2121.8 to 280.1) .23
Secondary outcomes
Symptom score during entire season 241 (150-398) 340 (189-503) 76 (25.9 to 133.5) .09
Medication score during entire season 254 (113-358) 255 (119-405) 21 (2125.0 to 157.0) .83
CSMS during peak season 342 (242-476) 363 (242-546) 18 (273.2 to 127.5) .51
Nasal symptom score during entire season 119 (80-205) 173 (123-207) 40 (13.3 to 71.5) .02
Mouth symptom score during entire season 14 (4-43) 38 (8-90) 14 (4.9 to 32.0) .02
Eye symptom score during entire season 72 (48-145) 80 (41-153) 0 (216.0 to 17.6) .85
Lung symptom score during entire season 11 (0-21) 17 (3-32) 9 (1.0 to 17.0) .05
Nasal allergic symptoms measured by VAS 118 (50-154) 162 (105-275) 68 (8.3 to 134.6) .008
Eye allergic symptoms measured by VAS 114 (42-159) 90 (32-197) 1 (252.8 to 62.0) .49
Global evaluation of symptom scores 3 (1-3) 3 (2-4) 1 (0.0 to 1.0) .25
Symptom-free days 44 (25-67) 34 (19-47) 212 (222.0 to 22.0) .04
No. of days prednisone used during entire season 0 (0-0) 0 (0-0) 0 (0 to 0) .33
Medication-free days 78 (66-98) 80 (65-92) 21 (220.0 to 17.0) .87
Mini-RQLQ 17 (10-22) 16 (13-23) 22.0 (25.89 to 1.88) .31
EQ-5D-5L 88 (84-94) 88 (83-94) 3 (228.4 to 35.2) .83
Data for primary outcome and all symptom scores represent AUC values. Median difference between groups was calculated by using stratified Hodges-Lehmann estimation. P
values are based on the stratified Mann-Whitney U (Van Elteren) test adjusted for stratification factors. P values for mini-RQLQ and EQ-5D-5L scores were based on a linear
mixed model adjusted for stratification factors. The entire grass pollen season was from May 13-August 31, 2013; the peak season was from June 12-July 26, 2013.
CSMS, Combined symptom and medication score; EQ-5D-5L, EuroQoL instrument.
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interquartile range [IQR], 6.3% to 25.4%) compared with the con-
trol group (median, 6.3%; IQR, 1.9% to 7.6%; P5 .04), whereas
expression of the TH1 cell marker CXCR3 was lower (median,
33.5% [IQR, 24.7% to 47.3%] vs 56% [IQR, 45.8% to 63.8%];
P 5 .01; Fig 4, B, and see Fig E2 in this article’s Online Reposi-
tory at www.jacionline.org). No differences were seen in expres-
sion of the TH17 marker CCR6 (data not shown). Insufficient T
cells could be expanded from diluent-challenged skin biopsyspecimens for analysis. Microarray transcriptional profiling per-
formed on cultured T cells from 15 allergen-challenged skin bi-
opsy specimens showed only 14 genes that were significantly
overexpressed in the active group (defined as >1.5-fold higher
expression than the control group and P < .05 by using a 3-way
ANOVA model), including IL-5, but no other TH2- or TH1-
related genes (see Table E4 in this article’s Online Repository
at www.jacionline.org; microarray Gene Expression Omnibus
Accession no. GSE72324; see Fig E3 in this article’s Online
TABLE IV. Effect of intradermal immunotherapy on daily and VAS organ symptom scores (intention-to-treat and post hoc
analysis)
Individual symptom
Control subjects (n 5 47),
median (IQR)
Intradermal immunotherapy
(n 5 46), median (IQR) Difference (95% CI) P value
Daily organ symptom scores
Nose
Sneezing 55 (35.0-71.0) 76 (43.3-103.0) 21 (7.0 to 34.0) .01
Blockage 36 (12.5-61.0) 41 (14.0-74.5) 6 (22.5 to 13.5) .33
Running 46 (22.5-65.4) 51 (30.0-81.5) 10 (23.0 to 22.8) .17
Mouth
Itching 8 (1.0-25.0) 19 (4.0-52.3) 4 (1.8 to 6.8) .06
Drying 3 (0.0-15.0) 7 (0.0-40.0) 3 (0.0 to 9.6) .18
Eyes
Itching 44 (26.0-72.5) 48 (21.0-68.0) 21 (25.0 to 2.0) .99
Redness/sore 14 (7.0-45.0) 17 (4.0-42.0) 21 (26.0 to 3.0) .55
Streaming 14 (2.0-24.0) 11 (2.0-19.0) 0 (24.0 to 3.0) .69
Swelling 5 (0.0-14.0) 2 (0.0-9.0) 22 (24.0 to 0.0) .03
Lungs
Breathlessness 0 (0.0-8.1) 0 (0.0-4.0) 0 (0.0 to 2.0) .27
Cough 1 (0.0-12.1) 8 (1.0-23.3) 2 (0.0 to 6.0) .02
Wheezing 0 (0.0-8.0) 3 (0.0-7.0) 0 (0.0 to 2.0) .25
Tightness 0 (0.0-4.0) 2 (0.0-4.0) 0 (0.0 to 2.0) .08
VAS organ symptom scores
Nose
Blockage 118 (39.1-178.8) 152 (71.4-238.7) 39 (1.6 to 82.8) .12
Running 117 (62.0-162.7) 169 (96.0-265.6) 58 (28.2 to 124.5) .006
Itching 81 (41.9-141.6) 138 (93.2-281.7) 64 (216.3 to 165.4) .003
Sneezing 125 (46.1-182.4) 187 (133.1-295.3) 77 (21.6 to 150.9) .006
Eyes
Itching 135 (41.9-217.8) 120 (53.7-248.3) 4 (235.3 to 46.1) .97
Watering 71 (33.6-119.4) 69 (21.0-129.5) 1 (240.5 to 55.5) .79
Data shown represent AUC values. Median difference between groups was calculated by using stratified Hodges-Lehmann estimation. P values were based on the stratified Mann-
Whitney U (Van Elteren) test adjusted for baseline stratification factors.
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relevant transcription factors). Gene ontology analysis did not
highlight a broader effect on TH2 or inflammation-related genes.
No significant treatment effect was seen on surface expression of
peripheral blood basophil activation markers (see Fig E4 in this
article’s Online Repository at www.jacionline.org) or on numbers
of eosinophils, neutrophils, CD31 T cells, and CD41 T cells after
immunohistochemical staining of diluent- and allergen-
challenged skin biopsy specimens (see Fig E5 in this article’s On-
line Repository at www.jacionline.org).Skin challenge results
Early-phase (15 minutes) and late-phase (24 hour) skin
responses could be measured in 86 participants 4 months after
the final intradermal allergen injection (September 2013) and then
repeated at either 7, 10, or 13 months. The size of the late-phase
responses in the control group was consistent with that reported in
our previous study under the same conditions (shown for com-
parison in Fig 4, C).5 In the present trial the late-phase response
was still suppressed 4 and 7 months after completing intradermal
allergen treatment (P 5 .03 for both time points) but not at 10 or
13 months. In comparison with the historical data, however, sup-
pression at these times was less than that which we observed
immediately after completing 6 injections (Fig 4, C), suggesting
that the suppressive effect on late-phase responses was wearing
off within 4 months.DISCUSSION
In this phase 2, randomized, double-blind, placebo-controlled
trial in adults with moderate-to-severe allergic rhinitis, preseaso-
nal treatment with intradermal grass pollen injections did not
affect the primary end point (combined symptom and medication
scores during the 2013 grass pollen season). These findings
repudiate our hypothesis that suppression of cutaneous late-phase
responses after repeated intradermal low-dose grass pollen
injections5 would be associated with clinical improvement of
allergic rhinitis. Intradermal allergen immunotherapy was associ-
ated with 44% worse allergic rhinitis nasal symptoms, as
measured by daily symptom scores, and 28% worse symptoms,
as measured by VAS scores, although the trial was neither de-
signed nor powered to detect deterioration of symptoms. These
findings were consistent when missing data were imputed. In
the per-protocol population, in addition to worsening of nasal
symptoms measured both daily and by VAS scores, we found
worsening of lung and mouth symptoms and significantly fewer
symptom-free days.
No serious adverse events attributable to grass pollen intrader-
mal allergen immunotherapy occurred. Ninety-two of the 93
participants completed the full injection course; 1 withdrew for
unrelated reasons. Five participants deviated significantly from
the protocol in use of rescue medications, mainly using excessive
antihistamines, topical nasal steroids, or eye drops. Two of these
participants also used prednisone without study physician guid-
ance. We are unable to account for why these 5 participants were
FIG 4. Immunologic outcomes.A, Levels of P pratense–specific IgE and IgG before and after completion of 7
intradermal allergen or histamine control injections. B, Expression of CRTH2 (TH2 marker) and CXCR3 (TH1
marker) on CD41 cells expanded from skin biopsy specimens (24 hours after skin challenge). C, Areas of
cutaneous late-phase responses (24 hours after intradermal skin challenge) 4 months and either 7, 10, or
13 months after treatment (September 2013). Late-phase response suppression was shown in our previous
study (Rotiroti et al5) immediately after 6 biweekly intradermal injections. Solid bars represent median
values. P values for pretreatment and posttreatment serology comparisons are based on the Wilcoxon
signed-rank test, and those for between-group IgE and IgG levels are based on analysis of covariance. P
values in Fig 4, B and C, are based on the Mann-Whitney U test.
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protocol population did not affect the conclusions of the study.
The strengths of this first randomized controlled trial of low-
dose intradermal immunotherapy include recruitment of partic-
ipants with moderate-to-severe symptoms in accordance with
ARIA classification; use of the primary outcome of combined
symptom and medication scores during the grass pollen season in
accordance with WAO guidance for allergic rhinitis trials; a low
level of missing daily diary card data; and successful blinding of
the active treatment. This was achieved through daily data entry
by participants, text reminders, and regular data collection
throughout the season.
The rationale for a trial of intradermal immunotherapy was
based on our previous study5 showing that this regimen systemi-
cally abrogated allergen-induced skin late responses and also pre-
vious clinical studies suggesting that epicutaneous11-13 and
intralymphatic14,15 immunotherapy might be clinically effective.
We hypothesized that intradermal injection of allergen might pro-
mote tolerogenic pathways through rapid uptake to regional
lymph nodes or possibly by dermal dendritic cell (DC) popula-
tions, which are relatively abundant compared with subcutaneous
tissue.16 Indeed, one of our active group participants reproducibly
demonstrated lymphangitis (see Fig E6 in this article’s Online Re-
pository at www.jacionline.org) within 30 minutes of each injec-
tion, which is suggestive of rapid lymphatic uptake of allergen.
We selected an allergen dose equivalent to 7 ng of the major
timothy grass pollen allergen Phl p 5 for several reasons.
First, we previously reported in a proof-of-concept study
conducted in a similar population that 6 biweekly injections at
the same dose led to almost complete attenuation of the cutaneous
late-phase response induced by these injections. This is compa-
rable with the effect on cutaneous late-phase responses seen after
high-dose subcutaneous immunotherapy17 and exceeds that after
treatment with sublingual grass pollen vaccines.18
Second, the average late-phase response induced by this dose
was approximately 10 cm in diameter, which we considered to be
at the limits of tolerability for patients. Although precise intra-
dermal grass dosages used in the uncontrolled historic studies of
Phillips are unknown,6,7 his aim during treatment was to induce
‘‘a local reaction about the size of the patient’s palm, which
should begin to subside within twenty four hours.’’
Our study has possible limitations. First, grass pollen doses
were not increased during the treatment course. This treatment
protocol was chosen because of our previous observation that
repeating the same dosewas sufficient to achieve almost complete
suppression of the late-phase response.
Second, injections were not continued throughout the grass
pollen season, although previous randomized controlled trials of
subcutaneous grass pollen immunotherapy have demonstrated
efficacy for preseasonal regimens.19
Late-phase skin responses were first measured at the end of the
2013 grass pollen season because performing such measurements
before or during collection of clinical outcome data would have
risked unblinding the trial. Late-phase responses still appeared
partially suppressed at this and the subsequent 7-month time
points. Nonetheless, this difference was less than we observed
immediately after completion of 6 intradermal injections in the
proof-of-concept study, suggesting that suppression is transient
and mostly reversed within 4 months. Therefore this effect might
be similar to that seen with transient desensitization during food
oral immunotherapy. The late cutaneous response is considered tobe at least partially T cell dependent and has been extensively
used as an experimental model for exploring mechanisms of
allergic disease.4,20 Our data suggest that either the late-phase
skin response is not relevant for disease expression or, more likely
in our view, that suppression of the late-phase response might be
necessary but not sufficient for clinical improvement after
allergen-specific immunotherapy.
The decrease in P pratense–, Phl p 1–, and Phl p 5–specific IgE
levels in the placebo group between the baseline (October 2012)
and follow-up measurement after 7 injections (May 2013) was
consistent with natural seasonal variation, as described in previ-
ous studies; levels of pollen-specific IgE increase during the grass
pollen season and then gradually decrease over the following
winter months.21,22 Similar changes also occur in pollen-
specific IgG antibodies.22 Intradermal immunotherapy arrested
the anticipated winter decrease, which was seen in the placebo
group. Therefore, taking into account the seasonal changes, intra-
dermal allergen immunotherapy stimulated IgE production. In
keeping with this and the exacerbation of nasal symptoms (and
other clinical parameters in the per-protocol population), T cells
cultured from skin punch biopsy explants in the intradermal
immunotherapy group expressed higher levels of the TH2 marker
CRTH2 and lower surface expression of the TH1 marker CXCR3
than biopsy specimens from placebo-treated subjects. Explor-
atory microarray analysis of these T cells was performed in a sub-
group only because of limited cell numbers. Although IL-5 was
one of only 14 genes overexpressed according to prespecified
criteria, gene ontology analysis did not highlight an effect on
other TH2- or inflammation-related genes. Also, post hoc analysis
with less stringent criteria did not highlight additional TH2- or
TH1-related genes. Therefore, although the clinical and other
immunologic findings indicate a priming effect, we interpret the
IL-5 microarray data in isolation with caution.
An intradermal priming effect could be consistent with
observational human studies linking cutaneous exposure to
peanut protein in children with atopic dermatitis with develop-
ment of peanut allergy, an effect more apparent in those with
impaired skin barrier function, which might promote dermal
allergen exposure.23,24 Our findings also raise the possibility that
intracutaneous exposure to aeroallergens, for example in patients
with atopic dermatitis with disrupted skin barrier function, might
have potential to promote or exacerbate respiratory allergic
disease. Such a link has been hypothesized as the basis of so-
called ‘‘atopic march’’ from atopic dermatitis to later develop-
ment of respiratory allergies.25
Previous attempts to develop novel immunotherapy approaches
based on epicutaneous allergen application have shown some
initial promise. Early-phase clinical trials have provided evidence
that allergen patches be effective for treatment of grass pollen
allergy,13 and similar patches are also under investigation for pea-
nut allergy.11,12 A potentially important immunologic difference
between epicutaneous and intradermal allergen immunotherapy
is in the types of antigen-presenting cells, particularly DC popu-
lations, likely to be encountered by allergen.16 In the epidermis
Langerhans cells predominate, although atopy patch tests also
induce infiltration by inflammatory dendritic epidermal cells,26
whereas in the dermis 3 major DC subtypes have been identi-
fied.27 Recent attention has focused on methods that enhance ker-
atinocyte activation and skin penetration by epicutaneous
allergen, such as skin stripping28 or use of microneedles.29 Skin
barrier disruption appears to promote dermal allergen exposure,30
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stripped skin has appeared to potentiate pre-existing systemic
TH2 responses.31 More recently, dermal DCs, but not Langerhans
cells, were found to elicit murine TH2 responses in response to ep-
icutaneous antigen.32
In conclusion, this is the first randomized controlled trial to
directly evaluate the efficacy of intradermal grass pollen immu-
notherapy, and the results suggest that this approach is not
clinically effective, despite local suppression of skin late-phase
responses. Moreover, the data suggest that this resulted in
immunologic priming and worsening of allergic rhinitis symp-
toms, providing direct evidence that dermal allergen exposure has
the potential to exacerbate rather than ameliorate allergic disease,
with implications for novel immunotherapy delivering allergen to
the skin.
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Clinical implications: Repeated intradermal allergen exposure
has the potential to exacerbate rather than ameliorate allergic
airway disease, with possible implications for novel immuno-
therapy strategies that promote dermal allergen exposure.REFERENCES
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Participants
Full inclusion criteria were adults aged 18 to 65 years with a history of
moderate-to-severe symptoms of grass pollen–induced allergic rhinitis ac-
cording to ARIA classificationE1 in May, June, or July for a minimum of
2 years, interfering with daily activities or sleep and remaining troublesome
despite treatment with medication. Participants were required to have a posi-
tive skin prick test response (wheal diameter >_3 mm) to P pratense together
with a positive specific IgE level (IgE class 2 or greater) against P pratense.
Women of childbearing age were included if they were willing to use an effec-
tive form of contraception for the duration of intradermal injections. Partici-
pants were able to consent and comply with study procedures.
Exclusion criteria were as follows: prebronchodilator FEV1 less than 70%
of predicted value at screening; seasonal grass pollen–induced asthma
requiring regular treatment with albuterol or inhaled corticosteroids (those
withmild seasonal grass pollen–induced asthma controlledwith occasional al-
buterol only were included); significant symptomatic seasonal allergic
rhinitis, asthma, or both caused by tree or weed pollen near or overlapping
the grass pollen season (patients with mild intermittent symptoms requiring
only occasional antihistamines were included); significant perennial rhinitis
(patients with mild intermittent symptoms requiring only occasional antihis-
tamines were included); an emergency department visit for asthma in the pre-
vious 12 months; chronic obstructive pulmonary disease; recurrent acute
sinusitis; chronic sinusitis; previous grass pollen immunotherapy within the
previous 5 years; previous life-threatening anaphylaxis or angioedema; his-
tory of intolerance of grass pollen immunotherapy or rescue medications; a
positive serum or urine pregnancy test result within 72 hours of enrollment;
lactating women; use of any investigational or immunosuppressive drug
within 30 days of screening; use of leukotriene receptor antagonists,
b-blockers, calcium-channel blockers, tricyclic antidepressants, monoamine
oxidase inhibitors, or anti-IgE mAb; a medical condition that the investigator
deemed incompatible with participation in the trial; infection of the upper res-
piratory tract, sinuses, or middle ear at randomization; and insufficient under-
standing of the trial protocol. Current smokers or subjects with greater than or
equal to 5 pack years of smoking were also ineligible.
Power calculations
Sample size calculations for the primary outcome (combined symptom and
medication score) were performed based on raw data from a previous clinical
trial of subcutaneous grass pollen immunotherapy.E2 The power calculation
was conservatively based on the detection of a clinical effect size 80% of
that reported in that trial. By using this method and a 2-sided nonparametric
test based on a Monte Carlo approach, group sample sizes of 35 and 35
achieved 90% power to detect such a difference in AUC of the combined
symptom and medication scores at a significance level of .05. The sample
size was increased by a further 15% to 40 in each arm to make allowance
for the unknown distribution of the primary outcome and based on the lower
bound for the asymptotic relative efficiency of the Mann-Whitney U test.
Further accounting for a postrandomization dropout rate of up to 10%, which
is consistent with previous trials of grass pollen immunotherapy, a total sample
size of 90 (45 each arm) was estimated as required.
Skin biopsy randomization
In August 2013, the King’s Clinical Trial Unit randomly selected participants
to be approached toundergo skinbiopsies. Thefirst 40participantswhoconsented
then underwent biopsy. Also in August 2013, all participants were randomized a
second time to one of 3 groups for repeat intradermal allergen injections at 7, 10,
or 13 months after the final intradermal immunotherapy or control injection to
assess whether low-dose intradermal allergen immunotherapy was associated
with prolonged suppression of skin responses.
Masking
All physicians, researchers, research nurses, outcome assessors, and patients
were blinded to treatment allocation until primary and secondary analyseswere
complete. Active and control study medication vials appeared identical. Onlythe King’s Clinical Trial Unit randomization provider and the manufacturing
pharmacy had access to blinding information. Unmasking could be performed
for emergencies only. To verify blinding, participants guessedwhether they had
received the active or control intervention after the pollen season.
Procedures
Each active intradermal allergen injection contained 10 BU (33.3 SQ-U) of
P pratense soluble grass pollen extract (Aquagen SQ Timothy; ALK-Abello)
in a 20-mL volume (ie, 500 BU/mL [1666.7 SQ-U/mL]). Individual vials for
each participant and each visit were preprepared and prelabeled by Guy’s
Hospital Pharmacy under good manufacturing practice conditions. In brief,
Aquagen SQ Timothy grass pollen extract was reconstituted in
manufacturer-supplied diluent to the maximum recommended concentration
(30,000 BU/mL [100,000 SQ-U/mL] ie, 603 final working strength; shelf
life of 6 months at 28C to 88C after reconstitution), and 0.15 mL was placed
in aliquots into glass study vials. At each visit, for intradermal injection, the
investigator added 8.85 mL of clinical grade 0.9% normal saline at ambient
temperature to the vial corresponding to that participant’s visit to achieve a
60-fold dilution. Twenty microliters was then aspirated from this vial and
administered directly. The allergen required dilution on the day of administra-
tion because the recommended shelf life of Aquagen SQTimothyGrass Pollen
extract at 500 BU/ml (1666.7 SQ-U/mL) is 14 days. The control intervention
was histamine only administered at a concentration of 100 mg/mL for the first
and second injections. Histamine concentrations were reduced to 30 mg/mL
for the third and fourth injections and 10mg/mL for the fifth, sixth, and seventh
injections to help preserve blinding. Histamine was also placed in aliquots in
study vials at 603 final working strength in 0.15-mL volumes for dilutionwith
8.85 mL of clinical grade 0.9% normal saline immediately before injection to
match the grass pollen extract dilution and preserve blinding. Active and con-
trol study medications appeared identical.
The injection site was alternated between the left and right arms at each
visit. Intradermal injections were administered in a 20-mL volume by using a
29-gauge insulin syringe (Micro-Fine; BD Biosciences, Oxford, United
Kingdom). In the event of an injection being administered too deeply (ie,
into subcutaneous tissue) to elicit an immediate injection ‘‘bleb’’ and
subsequent characteristic wheal, the injection was repeated 1 cm from the
original site. After an intradermal injection, participants were able to take an
antihistamine to reduce the local itching and swelling, if they wished.
Study outcomes
The primary outcomewas a combined symptom and medication score during
the grass pollen season (May 13-August 31, 2013; 111 days), as recommended by
WAO guidelines for allergic rhinitis immunotherapy trials.E3 Participants scored
symptoms from 0 to 3 in the nose (sneezing, blockage, and running), eye (itching,
redness, tears, and swelling), mouth, and throat (itching and dryness), and chest
(breathlessness, cough, wheezing, and tightness). Daily rescue medication was
scored as follows: desloratadine, 5mg, up to 1 tablet daily (6 points daily); olopa-
tadine eye drops, 1 mg/mL, up to 1 drop per eye twice daily (1.5 points per drop;
maximum, 6 points daily); fluticasone nasal spray, 50mg per spray, up to 2 sprays
per nostril once daily (2 points per spray; maximum, 8 points daily); and predni-
sone, 5mgper tablet, up to 6 tablets daily (2points per tablet;maximum,12points
daily). Symptom andmedication scores were expressed as the AUC for the entire
grass pollen season. Scores for symptoms (maximum, 39 points daily) and med-
ications (maximum, 32 points daily) were normalized before combining, as rec-
ommended by the WAO.E3
Safety
Adverse events. Adverse events and side effects were recorded from
the first treatment injection throughout the study regardless of severity or
relation to study participation. As a precaution against systemic allergic
reactions, all participants were observed after the first injection for 1 hour, and
if there was no systemic reaction, they were observed for 30 minutes after
subsequent injections. In the event of experiencing a grade 1 reaction, the
observation period for that subject remained at 1 hour after subsequent
injections.
*The following link has been created to allow review of record GSE72324 while it
remains in private status: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token5
evsfsmqyxdgffod&acc5GSE72324.
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1. symptoms caused by aeroallergen exposure (ie, nasal blockage, rhinor-
rhea, itching, or sneezing; itching, watering, redness, or swelling of the
eyes; itching or dryness of the mouth/throat; or breathless, cough,
wheeze, and chest tightness);
2. transient discomfort from intradermal injections;
3. appearance of an itchy edematous wheal with surrounding erythema
after intradermal injection;
4. appearance of swelling (edema) within hours of intradermal injection;
5. temporary discomfort, bleeding, bruising, and swelling at the needle
site after venesection; and
6. mild localized itching arising from skin prick testing during screening.
Withdrawal criteria and stopping rules. The prespecified
criteria for discontinuation of the study therapy (active or control) were as
follows:
1. inability or failure to attend intervention within 3 weeks of previous
allergen/histamine administration;
2. inability or failure to receive 7 or 8 injections within the dates
specified;
3. 2 grade 2 systemic reactions or a single systemic reaction of grade 3 or
greater after administration of study therapy, with systemic reactions
graded according to the WAO criteriaE4:
A. Grade 1: symptoms of 1 organ system (cutaneous, upper respira-
tory tract, conjunctival, gastrointestinal, and other);
B. Grade 2: symptoms of more than 1 organ system present or asthma
symptoms/signs (cough, wheezing, and shortness of breath but
<40% decrease in peak expiratory flow or FEV1);
C. Grade 3: asthma symptoms/signs (with >_40% decrease in peak
expiratory flow or FEV1), upper respiratory tract (laryngeal, uvula,
and tongue) edema with or without stridor; or
D. Grade 4: respiratory failure or hypotension with or without loss of
consciousness;
4. an adverse event that, in the judgment of the principal investigator or
the medical monitor, presented an unacceptable consequence or risk to
the participant;
5. an illness or infection not associated with the condition under study
and that required treatment not consistent with protocol requirements
or if a participant had an intercurrent illness that, in the judgment of
the principal investigator, in any way justified discontinuation;
6. an inability or unwillingness to comply with the study protocol, with
the protocol deviations being sufficient to jeopardize the participant’s
well-being or the integrity of the study; and
7. pregnancy occurring during study participation.
Predefined study stopping rules included the occurrence of 5 grade 3
reactions or a single grade 4 reaction.
Intradermal skin challenge testing
All patients underwent intradermal skin challenge testing 4 months after the
final intradermal allergen immunotherapy or control injection (September 2013).
Participants were then randomized to undergo a repeat follow-up test at either 7,
10, or 13 months to assess persistence of late response suppression by comparing
late-phase response sizes in those who had received active intradermal
immunotherapy or the control intervention. The procedure for the intradermal
skin challenge testing and the dose of allergen used was identical to that for an
active intradermal allergen immunotherapy injection. In brief, grass pollen extract
(10BU, equivalent to 33.3 SQ-U, ofAquagen SQTimothy; ALK-Abello) in a 20-
mL volume of allergen diluent was injected intradermally into the extensor aspect
of each forearm.A negative control injection of 20mLof diluentwas injected into
the contralateral forearm. Participants were asked to refrain from taking
antihistamines or oral steroids for a minimum of 5 days and 2 weeks beforehand,
respectively. Early-phase responses were measured 15 minutes after the intrader-
mal injection. Thewheal outlinewas traced and transferred into the patient record.
Late-phase responses were measured after 24 hours by means of palpation of the
outline of edema. The area of the late response was also traced and transferred tothe patient record. A single clinician performed all measurements under double-
blind conditions. The early- and late-phase response areas were calculated from
scaled scanned images of the tracings with NIS Elements v4.2 software (Nikon
Instruments, Tokyo, Japan). Early- and late-phase response areas were then
compared in the intradermal immunotherapy and control arms at each time point.
Skin biopsy
Forty participants (20 in each trial arm) were randomized to undergo 3-mm
skin punch biopsies immediately after measurement of late-phase responses
(ie, 24 hours after challenge) 4 months after completing their final treatment
injections in September 2013. Biopsy specimens were collected from both
allergen-challenged and diluent control sites. Local anesthesia was achieved
with 10mg/mL lidocaine hydrochloridewith adrenaline 1/200,000 (5mg/mL).
In the first 20 subjects, biopsy specimens were divided with a scalpel into 2
pieces, and one-half piecewas fixed in 4% paraformaldehyde (Sigma-Aldrich,
Poole, United Kingdom) for 2 hours. In the rest of the subjects, entire biopsy
specimens were processed for immunohistochemistry by means of fixation in
4% paraformaldehyde at room temperature for 4 hours. After washing twice in
15% sucrose, biopsy specimens were mounted in OCT embedding medium
(Bayer UK, Basingstoke, United Kingdom) and stored at 2808C pending
analysis. The remaining unfixed half-biopsy pieces were cultured directly for
T-cell analysis.
Analysis of T cells cultured from skin biopsy
specimens
Skin biopsy tissue was finely dissected and resuspended in complete
medium (RPMI supplemented with 10% FCS, penicillin [100 U/mL],
streptomycin [100 mg/mL], and L-glutamine (2 mmol/L; all from Life
Technologies, Warrington, United Kingdom). Tissues were then cultured at
378C in a humidified atmosphere containing 5% CO2 in the presence of IL-2
(50 U/mL). After 3 to 4 days, cells were passed through a 0.2-mm cell strainer
to obtain single-cell suspensions and restimulated with immobilized anti-
CD3/CD28 antibodies for a further 3 days, followed by expansion for
4 days in the presence of IL-2.
Expanded T cells were stained with the viability dye eFluor 780
(eBioscience, Vienna, Austria) before surface staining with anti-CD4
peridinin-chlorophyll-protein complex–Cy5.5 (BioLegend, London, United
Kingdom), anti-CD8 Brilliant Violet 510 (BD Biosciences), anti-CRTH2
phycoerythrin (PE; BioLegend), anti-CXCR3 Brilliant Violet 421 (Bio-
Legend), anti-CCR6 PE-Cy7 (BD Biosciences), and anti-IL-25 receptor
Alexa Fluor 647 (a kind gift of Dr Andrew McKenzie). Samples were
resuspended (FACSFlow, BD Biosciences) for flow cytometric analysis
(FACSCalibur, BD Biosciences). Data were analyzed with FlowJo v7.6
software (TreeStar, Ashland, Ore).
For microarray studies, cells were activated for 4 hours with ionomycin
(500 ng/mL) and phorbol 12-myristate 13-acetate (5 ng/mL; both fromSigma-
Aldrich). RNAwas isolated from cell pellets by using the miRNeasy mini kit
and RNeasy MinElute cleanup kit (Qiagen, Manchester, United Kingdom),
according to the manufacturer’s instructions. cDNA synthesis and amplifica-
tion were performed with the Ovation PicoSLWTA system V2 kit (NuGEN,
Leek, The Netherlands) per the manufacturer’s instructions. Purity and yield
were then analyzed by using the Bioanalyzer platform (Agilent, Stockport,
United Kingdom) and the NanoDrop 2000 spectrophotometer (Thermo
Scientific, Loughborough, United Kingdom), respectively, before amplified
cDNA was biotin labeled with the NuGEN Encore BiotinIL Module,
according to the manufacturer’s instructions. Biotin-labeled cDNA was
hybridized to an Illumina Human HT-12 v4 Expression BeadChip before
scanning with the iScan system (Illumina, Essex, United Kingdom) with
GenomeStudio software. Data analysis was performed with the Partek
Genomics Suit software (Partek, St Louis, Mo).*
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Immunohistochemical staining of skin biopsy specimens was performed
with the modified alkaline phosphatase–anti-alkaline phosphatase (APAAP)
method to stain for eosinophils, neutrophils, CD41 T cells, and CD31
T cells.E5,E6 In brief, 8- to 10-mm thickness tissue sections were air-dried over-
night on poly-L-lysine–coated slides. For immunostaining, slides were incu-
bated at room temperature in a humidified chamber with the primary mouse
mAb (neutrophil elastase; Dako, Ely, United Kingdom; eosinophilmajor basic
protein; Abcam, Cambridge, United Kingdom; or CD3 and CD4, both from
Dako) suspended in 5% human serum/PBS for predetermined optimized incu-
bation times. Sections were then washed in PBS and incubated with rabbit
anti-mouse immunoglobulin (Dako) for 30 minutes and then washed again.
Slides were then incubated with a third layer of soluble complexes of AP
and mouse anti-APAAP (Serotec, Kidlington, United Kingdom) for 30 mi-
nutes, washed, and developed with Fast Red (Sigma-Aldrich) for a further
20 minutes. Sections were washed extensively in PBS before counterstaining
with Harris’ hematoxylin (BDH, Poole, United Kingdom) and mounted in
glycerol gel. For negative controls, each primary antibody was substituted
with the appropriate isotype-matched irrelevant mAb. Slides were counted
blind in random order by 2 observers. Allergen and diluent biopsy sections
were evaluated from each subject. The total number of positive cells was ex-
pressed as the number of cells per squaremillimeter of biopsy specimen. Inter-
observer variability was 7%, as assessed on repeat counts of 19 slides. The
difference between the 2 counts was plotted against the mean of the 2 counts;
all but one of the differences fell within 2 SDs of the mean difference, indi-
cating satisfactory agreement between observers.
Serum antibody measurements
Sera were analyzed for concentrations of P pratense–specific IgG, IgG4,
and IgE and IgE specific to the major allergens Phl p 5 and Phl p 1 by using
a commercial assay system, according to the manufacturer’s instructions (Im-
munoCAP; Thermo Fisher Scientific, Horsham United Kingdom).
Basophil activation test
Basophil activation tests were performed in 92 participants after
administration of the final intradermal allergen immunotherapy or controlinjection (May 2013). Whole blood was collected and tested within 2 hours
of sampling under blinded conditions by a single investigator (A.G.).
Heparinized whole blood was immunostained with anti-human CD3 PE-
Cy7 (BD Biosciences), CD294 PE (Miltenyi Biotec, Woking, United
Kingdom), CD203c peridinin-chlorophyll-protein complex–Cy5.5 (Bio-
Legend), CD303 allophycocyanin (Miltenyi Biotec), CD107a Brilliant
Violet 421 (BioLegend), CD63 FITC (BioLegend), and isotype controls.
Basophils were then stimulated with anti-human IgE (1000 ng/mL,
positive control; Abcam) or P pratense extract (ALK-Abello) at 10 and
100 ng/mL for 15 minutes at 378C. Samples were then lysed (BD FACS
Lysing Solution, BD Biosciences), washed, and resuspended (CellFix,
BD Biosciences) for flow cytometric analysis (FACSCalibur, BD Biosci-
ences). Data were analyzed with FlowJo v7.6 software (TreeStar), gating
on CD32CD3032CD2941 basophils. Basophil activation was expression
as the percentage CD631, CD203c1, or CD107a1 basophils of the entire
basophil population.
FIG E1. Effects of intradermal immunotherapy on Phl p 5– (A) and Phl p 1– (B) specific IgE. Levels of IgE spe-
cific for the major allergens Phl p 5 and Phl p 1 before and after completion of 7 intradermal allergen or his-
tamine control injections are shown. P values for pretreatment and posttreatment comparisons were based
on the Wilcoxon signed-rank test. P values for between-group comparisons were based on analysis of
covariance.
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FIG E2. Flow cytometric analysis of CD41 T cells from skin biopsy explants. Representative flow cytometric
plots illustrating surface staining for CCR6, CXCR3, and CRTH2 gated on skin biopsy-derived CD41 T cells in
a participant who received histamine control (left) and a participant who received grass pollen intradermal
injections (right) are shown.
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FIG E3. Heat map showing expression of selected genes associated with
TH1/TH2 phenotypes and allergic inflammatory responses.
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FIG E4. Basophil activation tests. Percentages of basophils staining posi-
tive for the activation markers CD63 (A), CD107a (B), and CD203c (C) are
shown. Whole blood was stimulated under the conditions shown. P values
are based on the Mann-Whitney U test.
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FIG E5. Immunohistochemistry analysis of skin biopsy specimens. Comparison of allergen-induced
inflammatory cell numbers in skin biopsy specimens from intradermal immunotherapy and control arm
participants. Data shown indicate numbers of neutrophils (A), eosinophils (B), CD31 cells (C), and CD41 cells
(D) in skin biopsy specimens taken after diluent and P Pratense intradermal skin challenges in September
2013. Cells were stained by using the APAAP method. Solid bars represent median values. P values
comparing diluent- and allergen-challenged biopsy specimens are based on the Wilcoxon signed-rank
test. P values for between-group comparisons are based on analysis of covariance.
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FIG E6. Lymphangitis in a participant who received active intradermal
immunotherapy. The photograph was taken 40 minutes after intradermal
injection.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
SLOVICK ET AL 10.e9
TABLE E1. Verification of participant blinding
Patient guess trial arm
Trial arm
Control
subjects
(n 5 43)
Subjects
receiving
intradermal
immunotherapy
(n 5 44)
Intradermal immunotherapy (n 5 44) 22 22
Control (n 5 43) 21 22
At the end of the pollen season, participants verified blinding by guessing whether
they had received active or control treatment.
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TABLE E2. Effect of intradermal immunotherapy on primary and secondary outcomes (intention-to-treat analysis)
Clinical outcome
Control subjects
(n 5 47), median (IQR)
Intradermal
immunotherapy
(n 5 46),
median (IQR) Difference (95% CI) P value
Primary outcome
CSMS during entire season 509 (365-738) 502 (333-841) 8 (2174.7 to 210.9) .91
Secondary outcomes
Symptom score during entire season 264 (156-434) 335 (183-525) 61 (27.8 to 123.2) .22
Medication score during entire season 263 (129-482) 242 (116-405) 224 (2173.1 to 107.5) .39
CSMS score during peak season 370 (292-573) 363 (232-570) 211 (295.8 to 77.5) .80
Nasal symptom score during entire season 131 (80-200) 178 (120-218) 33 (0.3 to 68.5) .03
Mouth symptom score during entire season 14 (6-45) 39 (8-90) 11 (3.1 to 26.1) .05
Eye symptom score during entire season 78 (52-180) 79 (41-158) 27 (220.0 to 3.0) .51
Lung symptom score during entire season 12 (0-40) 20 (3-32) 4 (21.0 to 15.3) .17
Nasal allergic symptoms measured by VAS 124 (66-166) 162 (107-275) 59 (23.7 to 133.2) .02
Eye allergic symptoms measured by VAS 112 (42-169) 97 (37-197) 2 (245.6 to 49.0) .56
Global evaluation of symptom scores 3 (1-3) 3 (2-4) 0 (0 to 1) .43
Symptom-free days 41 (23-61) 35 (19-53) 26 (217 to 3) .15
No. of days prednisone used during entire season 0 (0-0) 0 (0-0) 0 (0 to 0) .36
Medication-free days 76 (56-94) 81 (65-93) 4 (211.0 to 21.0) .22
Mini-RQLQ 18 (10-25) 16 (13-23) 20.3 (24.2 to 3.7) .89
EQ-5D-5L 88 (81-94) 87 (83-94) 9 (224.8 to 43.6) .59
Missing data were imputed. Data for the primary outcome and all symptom scores represent AUC values. Median difference between groups was calculated by using stratified
Hodges-Lehmann estimation. P values were based on the stratified Mann-Whitney U (Van Elteren) test adjusted for stratification factors. P values for mini-RQLQ and EQ-5D-5L
scores were based on a linear mixed model adjusted for stratification factors. The entire grass pollen season was from May 13-August 31, 2013; the peak season was from June 12-
July 26, 2013.
CSMS, Combined symptom and medication score; EQ-5D-5L, EuroQoL instrument.
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TABLE E3. Frequency of adverse events reported from first intradermal allergen immunotherapy or control injection until end of
pollen season
Control subjects (n 5 47)
Subjects receiving intradermal
immunotherapy (n 5 46)
No. of
participants
with >_1 AE
Percentage of
participants
No. of
events
Event
rate
(%)
No. of
participants
with >_1 AE
Percentage of
participants
No. of
events
Event
rate
(%)
Any AEs 42 89 145 40 87 148
Serious AE 2 4.3 2 1.4 1 2.2 1 0.7
Tonsillitis 0 0 0 0 1 2.2 1 0.7
Overnight stay for polysomnography 1 2.1 1 0.7 0 0 0 0
Extraction of infected dental plate 1 2.1 1 0.7 0 0 0 0
Relation of AE to treatment
Definite/probable 6 13 14 9.7 3 6.5 15 10
Possible 0 0 0 0 0 0 0 0
Remote 34 72 70 48 30 65 68 46
None 34 72 61 42 32 70 65 44
AE withdrawals 0 0 0 0 0 0 0 0
Systemic Adverse reactions 6 13 13 9.0 3 6.5 15 10
Generalized pruritus 4 8.5 9 6.2 2 4.3 8 5.4
IgE-mediated lymphangitis 0 0 0 0 1 2.2 7 4.7
Lightheadedness 2 4.3 2 1.4 0 0 0 0
Facial flushing/feeling hot 2 4.3 3 2.1 0 0 0 0
Systemic adverse reactions*
Grade 1 6 13 12 8.3 3 6.5 15 10
Grade 2 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0
Grade 4 0 0 0 0 0 0 0 0
Statistical comparison was done by using the Fisher exact test for 5 or fewer events and the x2 test for more than 5 events.
AE, Adverse event.
*Classified by using the World Allergy Organization grading system for systemic reactions to subcutaneous immunotherapy.E3
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TABLE E4. Microarray gene expression profiles of activated
CD41 T cells derived from skin biopsy explants
Gene P value Fold difference
Intradermal immunotherapy down vs control group
LOC100133042 .02 21.80
CEP55 .03 21.78
GFOD1 .00 21.77
HIST2H2AB .04 21.62
H2AFZ .02 21.61
LOC730534 .01 21.57
HSD17B4 .02 21.57
HIST1H2AD .03 21.56
HDAC1 .01 21.55
CCL3L1 .03 21.53
CALR .02 21.52
CDCA5 .01 21.52
PRDX5 .01 21.51
FEN1 .02 21.50
Intradermal immunotherapy up vs control group
EPS15 .02 1.51
MYB .01 1.52
GK .03 1.53
RNASET2 .03 1.55
LOC729383 .02 1.56
GPR171 .00 1.59
LOC729387 .04 1.60
SLC11A2 .02 1.60
HS.508682 .04 1.68
IL5 .03 1.71
GBP5 .05 1.79
TNFSF8 .01 1.79
TNIP3 .03 1.87
CENTA1 .05 2.11
Data were analyzed by using the 3 way-ANOVA model.
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